Considering Your Treatment Options to Better Manage CML
With ongoing trials for new drugs, such as ponatinib, and the expanding use of dasatinib and nilotinib for CML, patients and their physicians have more options than ever. So how does one decide? In this interview from ASH 2011, Dr. Michael Mauro explains considerations related to changes in therapy; how best to manage side effects and avoid the risk of "running out" of potential drugs. Dr. Mauro stresses, as always, that active dialog, treatment adherence and "lots of information" will help physicians guide their patients to the right treatment strategy.
Experts & Guests
Michael Mauro, M.D.
Professor of Medicine, Division of Hematology and Medical Oncology, Oregon Health & Science UniversityDr. Michael Mauro is Professor of Medicine in the Division of Hematology and Medical Oncology at Oregon Health Science University. He received his medical degree from Dartmouth Medical School in New Hampshire and went on to complete his residency at New York Hospital-Cornell University Medical Center. Dr. Mauro’s clinical focus is leukemia, with a particular interest in CML. more >